Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Navepegritide: First Approval.

Drugs·2026

Same author

Pixavir Marboxil: First Approval.

Drugs·2026

Same author

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Same author

Correction: Donanemab: First Approval.

Drugs·2024

Same author

Donanemab: First Approval.

Drugs·2024

Same author

Alirocumab: Pediatric First Approval.

Paediatric drugs·2024

Search research articles

Related Experiment Video

Updated: May 10, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Sotatercept: First Approval.

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|June 21, 2024

Summary

This summary is machine-generated.

Sotatercept is a new treatment for pulmonary arterial hypertension that improves exercise capacity and reduces worsening events. It has recently gained US approval for adults with WHO Group 1 pulmonary arterial hypertension.

More Related Videos

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: May 10, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Pharmacology
Cardiovascular Medicine
Drug Development

Background:

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by high blood pressure in the pulmonary arteries.
Current treatments for PAH aim to manage symptoms and slow disease progression, but often do not address underlying disease mechanisms.
Activin signalling plays a role in the pathophysiology of PAH.

Purpose of the Study:

To summarize the key milestones in the development of sotatercept, an activin signalling inhibitor.
To highlight the regulatory approval of sotatercept for the treatment of pulmonary arterial hypertension in the USA.

Main Methods:

Review of preclinical and clinical development data for sotatercept.
Analysis of regulatory submission and approval processes.

Main Results:

Sotatercept, an activin signalling inhibitor, has been developed for PAH treatment.
The drug demonstrated efficacy in increasing exercise capacity, improving World Health Organization (WHO) functional class, and reducing clinical worsening events in adults with WHO Group 1 PAH.
Sotatercept received US FDA approval for this indication.

Conclusions:

Sotatercept represents a novel therapeutic approach for pulmonary arterial hypertension by targeting activin signalling.
The approval marks a significant advancement in PAH treatment, offering a new option for patients.
Further research may explore sotatercept's long-term outcomes and potential in other patient populations or disease stages.